Superiority of [<sup>68</sup>Ga]Ga-FAPI-04/[<sup>18</sup>F]FAPI-42 PET/CT to [<sup>18</sup>F]FDG PET/CT in delineating the primary tumor and peritoneal metastasis in initial gastric cancer.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 35380229.
- Also identified by DOI 10.1007/s00330-022-08743-1.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study aimed to compare [<sup>68</sup>Ga]Ga-FAPI-04/[<sup>18</sup>F]FAPI-42 PET/CT with [<sup>18</sup>F]FDG PET/CT in the evaluation of initial gastric cancer. We retrospectively compared [<sup>68</sup>Ga]Ga-FAPI-04/[<sup>18</sup>F]FAPI-42 PET/CT with [<sup>18</sup>F]FDG PET/CT in patients with initial gastric cancer from September 2020 to March 2021. Lesion detectability and the uptake of lesions quantified by the maximum standardized uptake value (SUVmax) and target-to-background ratio (TBR) were compared between the two modalities using the Wilcoxon signed-rank test, Mann-Whitney U test, and McNemar's chi-square test. A total of 61 patients (37 males, aged 23-81 years) were included, of which 22 underwent radical gastrectomy. For primary lesions, higher uptake of [<sup>68</sup>Ga]Ga-FAPI-04/[<sup>18</sup>F]FAPI-42 was observed compared to [<sup>18</sup>F]FDG (median SUVmax, 14.60 vs 4.35, p < 0.001), resulting in higher positive detection using [<sup>68</sup>Ga]Ga-FAPI-04/[<sup>18</sup>F]FAPI-42 PET/CT than [<sup>18</sup>F]FDG PET/CT (95.1% vs 73.8%, p < 0.001), particularly for tumors with signet-ring cell carcinoma (SRCC) (96.4% vs 57.1%, p < 0.001). [<sup>68</sup>Ga]Ga-FAPI-04/[<sup>18</sup>F]FAPI-42 PET/CT detected more positive lymph nodes than [<sup>18</sup>F]FDG PET/CT (637 vs 407). However, both modalities underestimated N staging compared to pathological N staging. [<sup>68</sup>Ga]Ga-FAPI-04/[<sup>18</sup>F]FAPI-42 PET/CT showed a higher sensitivity (92.3% vs 53.8%, p = 0.002) and peritoneal cancer index score (18 vs 3, p < 0.001) in peritoneum metastasis and other suspect metastases compared to [<sup>18</sup>F]FDG PET/CT. Our findings indicate that [<sup>68</sup>Ga]Ga-FAPI-04/[<sup>18</sup>F]FAPI-42 PET/CT outperformed [<sup>18</sup>F]FDG PET/CT in the evaluation of primary tumors with SRCC and peritoneum metastasis in initial gastric cancer. However, no clinically useful improvement was seen in N staging. • The uptake of [<sup>68</sup>Ga]Ga-FAPI-04/[<sup>18</sup>F]FAPI-42 in primary tumor and metastasis was intensely higher than that of [<sup>18</sup>F]FDG (p < 0.001) in 61 patients with initial gastric cancer. • [<sup>68</sup>Ga]Ga-FAPI-04/[<sup>18</sup>F]FAPI-42 PET/CT had a higher sensitivity detection in primary tumors (95.1% vs 73.8%, p < 0.001) and peritoneal metastases (92.3% vs 53.8%, p = 0.002) than [<sup>18</sup>F]FDG PET/CT. • [<sup>68</sup>Ga]Ga-FAPI-04/[<sup>18</sup>F]FAPI-42 PET/CT depicted more positive lymph nodes than [<sup>18</sup>F]FDG PET/CT (637 vs 407); however, both underestimated N staging compared to pathological N staging.
Medical subject headings
- Peritoneal Neoplasms
- Stomach Neoplasms